ライフサイエンスコーパス: laboratory finding

1 th and without bile duct changes had similar laboratory findings.

2 , familial bone disease, or related abnormal laboratory findings.

3 to its variable clinical manifestations and laboratory findings.

4 s had been made on the basis of clinical and laboratory findings.

5 luid resuscitation, radiography results, and laboratory findings.

6 rrelated with surgical, histopathologic, and laboratory findings.

7 and could not be predicted by examination or laboratory findings.

8 re were no consistent physical, clinical, or laboratory findings.

9 ed to verify the credibility of quantitative laboratory findings.

10 d EoE-associated endoscopic, histologic, and laboratory findings.

11 ancy outcomes, including uterine Doppler and laboratory findings.

12 r US findings in the context of clinical and laboratory findings.

13 mation, comorbidities, and microbiologic and laboratory findings.

14 and chronic gastritis, based on clinical and laboratory findings.

15 scussed, and the results are consistent with laboratory findings.

16 mptoms, has 1 or more designated clinical or laboratory findings.

17 hosphatase in the serum were the most common laboratory findings.

18 On the basis of clinical and laboratory findings, 40 of these patients were treated f

19 igenic, with recent experimentation from our laboratory finding a direct correlation between large an

20 roid complications, comorbidity, and various laboratory findings, adjusting for the total number of v

21 Sharing of epidemiologic and laboratory findings allowed for the rapid identification

22 mation as to the application of clinical and laboratory findings and bone marrow histopathology as th

23 er understanding of the relationship between laboratory findings and clinical reactivity is needed.

24 o identify associations between clinical and laboratory findings and histological features.

25 al trials, we assessed the clinical history, laboratory findings and muscle strength and function in

26 We analyzed the clinical and laboratory findings and outcome of 173 patients hospital

27 nd distribution of symptoms and impairments, laboratory findings and outcomes are essentially alike.

28 The laboratory findings and physical examination were normal

29 correlation between antemortem clinical and laboratory findings and postmortem culture results, ther

30 veloped following consideration of symptoms, laboratory findings and relevant medical history, and in

31 ion and clinical complications, and examined laboratory findings and toxic effects.

32 of the inconclusive results of both clinical-laboratory findings and ultrasonography, CT imaging was

33 Reversible hemodilution was apparent in laboratory findings and weight gain.

34 e cases of HIES were scored for clinical and laboratory findings and were genotyped with polymorphic

35 mptoms weekly and monitored adverse effects, laboratory findings, and cardiovascular parameters.

36 lationships between patient characteristics, laboratory findings, and clinical HIT status.

37 is clinical treatment failures, interpreting laboratory findings, and correlating the 2 clearly remai

38 Data on presenting signs and symptoms, laboratory findings, and hospital course were collected.

39 ify EMD, as defined by physical examination, laboratory findings, and imaging results.

40 The neurologic manifestations, laboratory findings, and outcome of patients with West N

41 re available on its clinical manifestations, laboratory findings, and outcomes of those patients requ

42 Screening tools, laboratory findings, and physical findings can be helpfu

43 ion of thienopyridine exposure, clinical and laboratory findings, and survival were recorded.

44 ores were correlated with clinical features, laboratory findings, and treatment responses.

45 When laboratory findings are discordant with expected clinica

46 To exclude cirrhosis, combinations of normal laboratory findings are most useful.

47 The clinical manifestations and laboratory findings are reported of 6 consecutive patien

48 The laboratory findings are supported by recent field observ

49 ls (n = 29), from patients with diagnoses or laboratory findings associated with serologic cross-reac

50 estations of HIV infection, the physical and laboratory findings associated with them, and the therap

51 d clinical symptoms, as well as clinical and laboratory findings at the time of diagnosis, were recor

52 Clinical and laboratory findings at the time of presentation were eva

53 There were no significant differences in laboratory findings between the two groups, and many neo

54 not associate with demographic, clinical, or laboratory findings, but they significantly associated w

55 These studies showed the validity of laboratory findings by supporting the idea that tea cons

56 esenting symptoms, clinical examination, and laboratory findings can guide selection of diagnostic im

57 g treatment of HIV according to clinical and laboratory findings, cancer treatment plan (chemotherapy

58 As anatomy, physiology, and even laboratory findings change during pregnancy, the clinici

59 m the following 5 categories: radiologic and laboratory findings, clinical and functional status meas

60 of dilution and amplification supported our laboratory findings, demonstrating that the results are

61 eight; other vital signs and cardiometabolic laboratory findings did not differ between groups.

62 iagnostic term when clinical, histologic and laboratory findings do not allow for specific categoriza

63 AQP4-antibody is now the most important laboratory finding for the diagnosis of NMO.

64 We sought to describe clinical and laboratory findings for a large cohort of patients with

65 noses, evaluated consistency of RI and other laboratory findings for chemicals identified by the RI a

66 ve predictive value of specific clinical and laboratory findings for curable enteric infections excee

67 We evaluated clinical and laboratory findings for patients with erythema migrans w

68 Insights from clinical and laboratory findings have also been recently harnessed fo

69 miological, clinical, neuroradiagnostic, and laboratory findings have enhanced our diagnostic accurac

70 Some laboratory findings imply that imatinib may primarily af

71 he normal range in the blood and is a common laboratory finding in patients.

72 We report the clinical and laboratory findings in 11 patients in whom thrombotic th

73 one biopsy in 9 patients and clinical course/laboratory findings in 5.

74 , and the need for careful interpretation of laboratory findings in conjunction with clinical signs i

75 This report describes the clinical laboratory findings in golden hamsters experimentally in

76 tes, unique clinical features, MRI and other laboratory findings in NMO have been clarified further.

77 ncies were categorized based on clinical and laboratory findings in the affected patient.

78 lished studies and argue for the adoption of laboratory findings in the staging systems that are used

79 Clinical and laboratory findings in this disorder are similar to thos

80 Although none of the laboratory findings, including LPS hyporesponsiveness, i

81 Laboratory findings, including the growth of new blood v

82 cs of the history, physical examination, and laboratory findings, individually and in combination, in

83 cording to medical history, medications, and laboratory findings (insulin-like growth factor 1, folli

84 Implementing our laboratory findings into a global modeling framework sho

85 However, translating these laboratory findings into effective clinical strategies c

86 Translating the laboratory findings into the clinical environment where

87 unity-dwelling men to determine whether this laboratory finding is manifest at the population level.

88 of both the patient's clinical situation and laboratory findings is important for tailoring therapy o

89 The correlations among laboratory findings, liver stiffness, and fibrosis score

90 treatment of an in-stent restenotic lesion), laboratory findings (low baseline hemoglobin and reduced

91 and, evolutionary tradeoffs predict that the laboratory findings may not be relevant to human populat

92 oncept that in systemic lupus erythematosus, laboratory findings may not correlate well with the unde

93 The lack of characteristically abnormal laboratory findings may result in a delay in the proper

94 No specific pattern of signs, symptoms, or laboratory findings occurred with enough frequency to co

95 artate receptor, that is, the characteristic laboratory finding of anti-N-methyl-D-aspartate receptor

96 large health maintenance organization with a laboratory finding of CKD (defined as estimated GFR betw

97 We compared the clinical and laboratory findings of 15 patients with sudden-onset syn

98 We examined the clinical and laboratory findings of a consecutive series of patients

99 The patients with clinical or laboratory findings of elevated D-dimer level or elevate

100 40 consecutive patients with no clinical or laboratory findings of hemodialysis access dysfunction.

101 sing Tourette syndrome reflects clinical and laboratory findings of investigations of behavioral, neu

102 ophy in splenic tissues were compatible with laboratory findings of leukopenia, lymphopenia, and thro

103 study sought to investigate the clinical and laboratory findings of patients affected by sudden-onset

104 the clinical presentation, pathogenesis, and laboratory findings of patients with these two disorders

105 oning of the system and for extrapolation of laboratory findings of stressor impacts on specific comp

106 pretreatment and posttreatment clinical and laboratory findings of the case series patients.

107 a deterioration in the general condition and laboratory findings or appearance of new abdominal compl

108 were apparent on vital sign determinations, laboratory findings, or electrocardiographic measurement

109 anges from baseline in vital signs, clinical laboratory findings, or electrocardiography findings in

110 Based on history, clinical examination, and laboratory findings, patients may be placed in three cat

111 Clinical and laboratory findings persist despite cessation of vitamin

112 Recent laboratory findings provide exciting insights into a bid

113 Laboratory findings ranged widely and did not characteri

114 Of all laboratory findings readily available to the clinician,

115 e adverse drug effects were observed, and no laboratory findings required discontinuation of treatmen

116 Clinical symptoms and laboratory findings resembled those of classic acute sch

117 ncreatitis improved over a few days, and the laboratory findings returned to normal ranges.

118 Laboratory findings revealed an elevated white blood cel

119 Laboratory findings revealed inflammation with an increa

120 Our laboratory findings serve to reinforce field observation

121 These laboratory findings should not be interpreted as indicat

122 rature of > or = 40 degrees C), and abnormal laboratory findings (such as a pH <7.35, a blood urea ni

123 Laboratory findings (such as prothrombin time and biliru

124 Recent laboratory findings suggest that it might be possible to

125 Laboratory findings suggest that the foreskin is enriche

126 one had onward transmission, consistent with laboratory findings suggesting a secondary immune respon

127 poglycemia, rhabdomyolysis, arrhythmias, and laboratory findings suggestive of a defect in mitochondr

128 ive study, for 57 children with clinical and laboratory findings suggestive of APN, the 2 radiopharma

129 We studied three patients with symptoms and laboratory findings suggestive of human granulocytic ehr

130 ut chest radiographic changes or clinical or laboratory findings suggestive of pneumonia (nonpneumoni

131 k in one male with both a family history and laboratory findings suggestive of XLA.

132 These clinical and laboratory findings support the concept that telomerase

133 Taken together, the clinical analyses and laboratory findings support the interpretation that impr

134 w of recent clinical studies and correlative laboratory findings that advance our understanding of th

135 Our field results support laboratory findings that caching rates and distances by

136 nd any associated extracutaneous clinical or laboratory findings that may accompany them.

137 ng-term effects of therapy, as well as novel laboratory findings that may alter future treatment stra

138 cent studies assessing clinical features and laboratory findings that may help diagnose psychogenic m

139 fy the specific combinations of clinical and laboratory findings that presumably account for this dia

140 However, no clinical or laboratory findings that reliably distinguish X-linked d

141 hic characteristics, duration of illness and laboratory findings that we were able to obtain.

142 No clinical or laboratory findings that were present at MCD diagnosis p

143 ities in lung cancer, efforts of translating laboratory findings to clinical tests, and prospective o

144 ed in conjunction with the physical exam and laboratory findings to identify children at risk for IAI

145 o use the history, physical examination, and laboratory findings to identify structural causes and di

146 We related the laboratory findings to signs of sympathetic neurocircula

147 e are problems involved in generalizing from laboratory findings to the reporting of the symptoms of

148 re characterized by nonspecific clinical and laboratory findings, ultimately requiring a trial of dru

149 On the basis of clinical and laboratory findings, various forms of HES have been defi

150 ent of symptoms, endoscopic, histologic, and laboratory findings was carried out, were included.

151 ve tuberculin skin test alone among clinical laboratory findings was significantly associated with an

152 Clinical backgrounds, clinical symptoms, and laboratory findings were compared between neonates with

153 Clinical and laboratory findings were compared between patients who d

154 Clinical and laboratory findings were consistent with the EPO-depende

155 Typical laboratory findings were elevated C-reactive protein, le

156 The most frequent laboratory findings were lymphopenia, thrombocytopenia,

157 Abnormal laboratory findings were negatively associated with disc

158 Clinical and laboratory findings were non-specific, while imaging fea

159 Clinical features and laboratory findings were recorded for all 245 residents

160 Oral and general health data including laboratory findings were recorded from hospital records,

161 Data about clinical manifestations and laboratory findings were retrieved from medical records.

162 Although laboratory findings were similar for children with oligo

163 Field observations supported our laboratory findings where significant concentrations (42

164 However, laboratory findings with current methodologies are often

165 Typing is usually based on clinical and laboratory findings with monoclonal gammopathy evaluatio